Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). (Q41313041)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 September 2015

Language	Label	Description	Also known as
English	Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).	scientific article published on 25 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

0 references

Andreas Hochhaus

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Haifa Kathrin Al-Ali

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

C Kahl

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

R Krahl

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

C Becker

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

H G Sayer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

A Schulze

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Herold

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Hänel

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

S Scholl

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

L Uharek

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

G Maschmeyer

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

D Haehling

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

C Junghanß

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

N Peter

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

D Kämpfe

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

E Kettner

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

T Heinicke

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

T Fischer

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

U Kreibich

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

H-H Wolf

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

D Niederwieser

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

25 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

142

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

305-315

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

The role of hypomethylating agents in the treatment of elderly patients with AML.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Acute myeloid leukaemia (AML): treatment of the older patient

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Acute myeloid leukemia: treatment over 60.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

A classification of acute leukaemia for the 1990s

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Age-related clonal hematopoiesis associated with adverse outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Treating acute myeloid leukemia in older adults

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-2045-8

21 January 2018

Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The classification of acute leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/26407768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-015-2045-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

release_3lblodhvvvdubncyd2ehoxo3ru

1 reference

https://api.fatcat.wiki/v0/release/3lblodhvvvdubncyd2ehoxo3ru

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26407768%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41313041&oldid=2204462259"